Radiometal-labeled anti-VCAM-1 nanobodies as molecular tracers for atherosclerosis - impact of radiochemistry on pharmacokinetics.
VCAM-1 knock-down mice
mass effect
molecular imaging
single-domain antibody fragment
specific activity
vulnerable plaque
Journal
Biological chemistry
ISSN: 1437-4315
Titre abrégé: Biol Chem
Pays: Germany
ID NLM: 9700112
Informations de publication
Date de publication:
25 02 2019
25 02 2019
Historique:
received:
30
07
2018
accepted:
20
08
2018
pubmed:
22
9
2018
medline:
2
11
2019
entrez:
22
9
2018
Statut:
ppublish
Résumé
Radiolabeling of nanobodies with radiometals by chelation has the advantage of being simple, fast and easy to implement in clinical routine. In this study, we validated 68Ga/111In-labeled anti-VCAM-1 nanobodies as potential radiometal-based tracers for molecular imaging of atherosclerosis. Both showed specific targeting of atherosclerotic lesions in ApoE-/- mice. Nevertheless, uptake in lesions and constitutively VCAM-1 expressing organs was lower than previously reported for the 99mTc-labeled analog. We further investigated the impact of different radiolabeling strategies on the in vivo biodistribution of nanobody-based tracers. Comparison of the pharmacokinetics between 68Ga-, 18F-, 111In- and 99mTc-labeled anti-VCAM-1 nanobodies showed highest specific uptake for 99mTc-nanobody at all time-points, followed by the 68Ga-, 111In- and 18F-labeled tracer. No correlation was found with the estimated number of radioisotopes per nanobody, and mimicking specific activity of other radiolabeling methods did not result in an analogous biodistribution. We also demonstrated specificity of the tracer using mice with a VCAM-1 knocked-down phenotype, while showing for the first time the in vivo visualization of a protein knock-down using intrabodies. Conclusively, the chosen radiochemistry does have an important impact on the biodistribution of nanobodies, in particular on the specific targeting, but differences are not purely due to the tracer's specific activity.
Identifiants
pubmed: 30240352
doi: 10.1515/hsz-2018-0330
pii: hsz-2018-0330
doi:
Substances chimiques
Gallium Radioisotopes
0
Indium Radioisotopes
0
Single-Domain Antibodies
0
Vascular Cell Adhesion Molecule-1
0
Gallium-68
98B30EPP5S
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
323-332Références
Andrews, J.P.M., Fayad, Z.A., and Dweck, M.R. (2018). New methods to image unstable atherosclerotic plaques. Atherosclerosis 272, 118–128.
Bala, G., Blykers, A., Xavier, C., Descamps, B., Broisat, A., Ghezzi, C., Fagret, D., Van Camp, G., Caveliers, V., Vanhove, C., et al. (2016). Targeting of vascular cell adhesion molecule-1 by 18F-labeled nanobodies for PET/CT imaging of inflamed atherosclerotic plaques. Eur. Heart J. Cardiovasc. Imaging 17, 1001–1008.
Bala, G., Baudhuin, H., Remory, I., Gillis, K., Debie, P., Krasniqi, A., Lahoutte, T., Raes, G., Devoogdt, N., Cosyns, B., et al. (2018a). Evaluation of 99mTc-radiolabeled macrophage-mannose receptor-specific nanobodies for targeting of atherosclerotic lesions in mice. Mol. Imaging Biol. 20, 260–267.
Bala, G., Broisat, A., Lahoutte, T., and Hernot, S. (2018b). Translating molecular imaging of the vulnerable plaque-a vulnerable project? Mol. Imaging Biol. 20, 337–339.
Blykers, A., Schoonooghe, S., Xavier, C., D’Hoe, K., Laoui, D., D’Huyvetter, M., Vaneycken, I., Cleeren, F., Bormans, G., Heemskerk, J., et al. (2015). PET imaging of macrophage mannose receptor-expressing macrophages in tumor stroma using 18F-radiolabeled camelid single-domain antibody fragments. J. Nucl. Med. 56, 1265–1271.
Brasse, D. and Nonat, A. (2015). Radiometals: towards a new success story in nuclear imaging? Dalton Trans. 44, 4845–4858.
Broisat, A., Hernot, S., Toczek, J., De Vos, J., Riou, L.M., Martin, S., Ahmadi, M., Thielens, N., Wernery, U., Caveliers, V., et al. (2012). Nanobodies targeting mouse/human VCAM1 for the nuclear imaging of atherosclerotic lesions. Circ. Res. 110, 927–937.
Broisat, A., Toczek, J., Dumas, L.S., Ahmadi, M., Bacot, S., Perret, P., Slimani, L., Barone-Rochette, G., Soubies, A., Devoogdt, N., et al. (2014). 99mTc-cAbVCAM1-5 imaging is a sensitive and reproducible tool for the detection of inflamed atherosclerotic lesions in mice. J. Nucl. Med. 55, 1678–1684.
Chakravarty, R., Goel, S., and Cai, W. (2014). Nanobody: the “magic bullet” for molecular imaging? Theranostics 4, 386–398.
D’Huyvetter, M., De Vos, J., Xavier, C., Pruszynski, M., Sterckx, Y.G.J., Massa, S., Raes, G., Caveliers, V., Zalutsky, M., Lahoutte, T., et al. (2017). 131I-labeled anti-HER2 camelid sdAb as a theranostic tool in cancer treatment. Clin. Cancer Res. 23, 6616–6628.
Debie, P., Van Quathem, J., Hansen, I., Bala, G., Massa, S., Devoogdt, N., Xavier, C., and Hernot, S. (2017). Effect of dye and conjugation chemistry on the biodistribution profile of near-infrared-labeled nanobodies as tracers for image-guided surgery. Mol. Pharm. 14, 1145–1153.
Debie, P., Vanhoeij, M., Poortmans, N., Puttemans, J., Gillis, K., Devoogdt, N., Lahoutte, T., and Hernot, S. (2018). improved debulking of peritoneal tumor implants by near-infrared fluorescent nanobody image guidance in an experimental mouse model. Mol. Imaging Biol. 20, 361–367.
Dumas, L.S., Briand, F., Clerc, R., Brousseau, E., Montemagno, C., Ahmadi, M., Bacot, S., Soubies, A., Perret, P., Riou, L.M., et al. (2017). Evaluation of antiatherogenic properties of ezetimibe using 3H-labeled low-density-lipoprotein cholesterol and 99mTc-cAbVCAM1-5 SPECT in ApoE−/− mice fed the paigen diet. J. Nucl. Med. 58, 1088–1093.
Germano, G., Berman, D.S., and Slomka, P. (2016). Technical aspects of cardiac PET imaging and recent advances. Cardiol. Clin. 34, 13–23.
Goethals, L.R., Weytjens, C.D., De Geeter, F., Droogmans, S., Caveliers, V., Keyaerts, M., Vanhove, C., Van Camp, G., Bossuyt, A., and Lahoutte, T. (2009). Regional quantitative analysis of small animal myocardial sympathetic innervation and initial application in streptozotocin induced diabetes. Contrast Media. Mol. Imaging 4, 174–182.
Hernot, S., Unnikrishnan, S., Du, Z., Shevchenko, T., Cosyns, B., Broisat, A., Toczek, J., Caveliers, V., Muyldermans, S., Lahoutte, T., et al. (2012). Nanobody-coupled microbubbles as novel molecular tracer. J. Control Release 158, 346–353.
Jacobson, O., Kiesewetter, D.O., and Chen, X. (2014). Fluorine-18 radiochemistry, labeling strategies and synthetic routes. Bioconjug. Chem. 26, 1–18.
Keyaerts, M., Xavier, C., Heemskerk, J., Devoogdt, N., Everaert, H., Ackaert, C., Vanhoeij, M., Duhoux, F.P., Gevaert, T., Simon, P., et al. (2016). Phase I study of 68Ga-HER2-nanobody for PET/CT assessment of HER2 expression in breast carcinoma. J. Nucl. Med. 57, 27–33.
Konijnenberg, M.W., Breeman, W.A., de Blois, E., Chan, H.S., Boerman, O.C., Laverman, P., Kolenc-Peitl, P., Melis, M., and de Jong, M. (2014). Therapeutic application of CCK2R-targeting PP-F11: influence of particle range, activity and peptide amount. EJNMMI Res. 4, 47.
Krasniqi, A., D’Huyvetter, M., Xavier, C., Van der Jeught, K., Muyldermans, S., Van Der Heyden, J., Lahoutte, T., Tavernier, J., and Devoogdt, N. (2017). Theranostic radiolabeled anti-CD20 sdAb for targeted radionuclide therapy of non-Hodgkin lymphoma. Mol. Cancer Ther. 16, 2828–2839.
Krasniqi, A., D’Huyvetter, M., Devoogdt, N., Frejd, F.Y., Sorensen, J., Orlova, A., Keyaerts, M., and Tolmachev, V. (2018). Same-day imaging using small proteins: clinical experience and translational prospects in oncology. J. Nucl. Med. 59, 885–891.
Krishnan, H.S., Ma, L., Vasdev, N., and Liang, S.H. (2017). 18F-Labeling of sensitive biomolecules for positron emission tomography. Chemistry 23, 15553–15577.
Kung, M.P. and Kung, H.F. (2005). Mass effect of injected dose in small rodent imaging by SPECT and PET. Nucl. Med. Biol. 32, 673–678.
Marschall, A.L., Single, F.N., Schlarmann, K., Bosio, A., Strebe, N., van den Heuvel, J., Frenzel, A., and Dubel, S. (2014). Functional knock down of VCAM1 in mice mediated by endoplasmatic reticulum retained intrabodies. mAbs 6, 1394–1401.
Martiniova, L., Palatis, L., Etchebehere, E., and Ravizzini, G. (2016). Gallium-68 in medical imaging. Curr. Radiopharm. 9, 187–207.
Massa, S., Vikani, N., Betti, C., Ballet, S., Vanderhaegen, S., Steyaert, J., Descamps, B., Vanhove, C., Bunschoten, A., van Leeuwen, F.W., et al. (2016). Sortase A-mediated site-specific labeling of camelid single-domain antibody-fragments: a versatile strategy for multiple molecular imaging modalities. Contrast. Media Mol. Imaging. 11, 328–339.
Naghavi, M., Libby, P., Falk, E., Casscells, S.W., Litovsky, S., Rumberger, J., Badimon, J.J., Stefanadis, C., Moreno, P., Pasterkamp, G., et al. (2003). From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: part I. Circulation 108, 1664–1672.
Notni, J., Steiger, K., Hoffmann, F., Reich, D., Schwaiger, M., Kessler, H., and Wester, H.J. (2016). Variation of specific activities of 68Ga-aquibeprin and 68Ga-avebetrin enables selective PET imaging of different expression levels of integrins 5 1 and v 3. J. Nucl. Med. 57, 1618–1624.
Price, E.W. and Orvig, C. (2014). Matching chelators to radiometals for radiopharmaceuticals. Chem. Soc. Rev. 43, 260–290.
Quillard, T. and Libby, P. (2012). Molecular imaging of atherosclerosis for improving diagnostic and therapeutic development. Circ. Res. 111, 231–244.
Schroeder, R.P., De Blois, E., De Ridder, C.M., Van Weerden, W.M., Breeman, W.A., and de Jong, M. (2012). Improving radiopeptide pharmacokinetics by adjusting experimental conditions for bombesin receptor-targeted imaging of prostate cancer. Q. J. Nucl. Med. Mol. Imaging 56, 468–475.
Steeland, S., Vandenbroucke, R.E., and Libert, C. (2016). Nanobodies as therapeutics: big opportunities for small antibodies. Drug Discov. Today 21, 1076–1113.
Tarkin, J.M., Joshi, F.R., and Rudd, J.H. (2014). PET imaging of inflammation in atherosclerosis. Nat. Rev. Cardiol. 11, 443–457.
Tolmachev, V., Rosik, D., Wallberg, H., Sjoberg, A., Sandstrom, M., Hansson, M., Wennborg, A., and Orlova, A. (2010). Imaging of EGFR expression in murine xenografts using site-specifically labeled anti-EGFR 111In-DOTA-Z EGFR:2377 Affibody molecule: aspect of the injected tracer amount. Eur. J. Nucl. Med. Mol. Imaging 37, 613–622.
Tolmachev, V., Wallberg, H., Sandstrom, M., Hansson, M., Wennborg, A., and Orlova, A. (2011). Optimal specific radioactivity of anti-HER2 Affibody molecules enables discrimination between xenografts with high and low HER2 expression levels. Eur. J. Nucl. Med. Mol. Imaging 38, 531–539.
Vandesquille, M., Li, T., Po, C., Ganneau, C., Lenormand, P., Dudeffant, C., Czech, C., Grueninger, F., Duyckaerts, C., Delatour, B., et al. (2017). Chemically-defined camelid antibody bioconjugate for the magnetic resonance imaging of Alzheimer’s disease. mAbs 9, 1016–1027.
Vaneycken, I., Devoogdt, N., Van Gassen, N., Vincke, C., Xavier, C., Wernery, U., Muyldermans, S., Lahoutte, T., and Caveliers, V. (2011). Preclinical screening of anti-HER2 nanobodies for molecular imaging of breast cancer. FASEB J. 25, 2433–2446.
Velikyan, I. (2013). Prospective of 68Ga-radiopharmaceutical development. Theranostics 4, 47–80.
Xavier, C., Devoogdt, N., Hernot, S., Vaneycken, I., D’Huyvetter, M., De Vos, J., Massa, S., Lahoutte, T., and Caveliers, V. (2012). Site-specific labeling of his-tagged Nanobodies with 99mTc: a practical guide. Methods Mol. Biol. 911, 485–490.
Xavier, C., Vaneycken, I., D’Huyvetter, M., Heemskerk, J., Keyaerts, M., Vincke, C., Devoogdt, N., Muyldermans, S., Lahoutte, T., and Caveliers, V. (2013). Synthesis, preclinical validation, dosimetry, and toxicity of 68Ga-NOTA-anti-HER2 nanobodies for iPET imaging of HER2 receptor expression in cancer. J. Nucl. Med. 54, 776–784.